<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='1'><Row><AdverseSummary>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in April 2012.  The observed adverse events    within 30 min in   &lt;ulink linkType="Drug" linkID="2695"&gt;buprenorphine&lt;/ulink&gt; and morphine groups, respectively, were nausea (14 versus 12%), dizziness (14 versus 22%), and hypotension (4 versus 18%) [&lt;ulink linkType="Reference" linkID="1291739"&gt;1291739&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseSummary><Description>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive placebo along with either sublingual &lt;ulink linkType="Drug" linkID="2695"&gt;buprenorphine&lt;/ulink&gt;  (0.4 mg) or iv morphine sulphate (1 mg/ml).&lt;/para&gt;&lt;/ProtocolDescription&gt;</Description><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drugs>buprenorphine (sublingual, opioid dependence), Indivior</Drugs><Indications>Pain</Indications><OutcomeSummary>&lt;Outcomes&gt;&lt;para&gt;Results were published in April 2012.  At 30 and 60 min, mean pain scores were similar in    &lt;ulink linkType="Drug" linkID="2695"&gt;buprenorphine&lt;/ulink&gt; and morphine groups,  respectively (5.0 versus 5.0;  and 2.2 versus 2.2) [&lt;ulink linkType="Reference" linkID="1291739"&gt;1291739&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</OutcomeSummary><ProtocolTitle>Efficacy of Buprenorphine for Treatment of Acute Pain</ProtocolTitle><References>NCT01298297; TUMS-THESIS 88</References><TreatmentSummary>&lt;Regimens&gt;&lt;para&gt;Patients received  &lt;ulink linkType="Drug" linkID="2695"&gt;buprenorphine&lt;/ulink&gt; 0.4 mg sublingually or morphine 5 mg iv. Pain was assessed before the drug    administration and 30 and 60 min  after the drug administration [&lt;ulink linkType="Reference" linkID="1291739"&gt;1291739&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regimens&gt;</TreatmentSummary><Trial id="74875"/><TrialStatus>Completed</TrialStatus></Row></Rowset>